X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS GLENMARK PHARMA DR. DATSONS LABS/
GLENMARK PHARMA
 
P/E (TTM) x -10.9 19.1 - View Chart
P/BV x 0.2 3.4 4.8% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 DR. DATSONS LABS   GLENMARK PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
GLENMARK PHARMA
Mar-17
DR. DATSONS LABS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs126993 12.6%   
Low Rs31729 4.2%   
Sales per share (Unadj.) Rs133.0325.5 40.9%  
Earnings per share (Unadj.) Rs0.239.3 0.4%  
Cash flow per share (Unadj.) Rs6.648.7 13.6%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs128.8159.2 80.9%  
Shares outstanding (eoy) m31.66282.17 11.2%   
Bonus/Rights/Conversions FCCBESOP-  
Price / Sales ratio x0.62.6 22.2%   
Avg P/E ratio x516.121.9 2,355.0%  
P/CF ratio (eoy) x11.817.7 66.9%  
Price / Book Value ratio x0.65.4 11.2%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m2,477242,991 1.0%   
No. of employees `000NA13.0 0.0%   
Total wages/salary Rs m5616,408 0.3%   
Avg. sales/employee Rs ThNM7,083.9-  
Avg. wages/employee Rs ThNM1,265.4-  
Avg. net profit/employee Rs ThNM855.1-  
INCOME DATA
Net Sales Rs m4,21191,857 4.6%  
Other income Rs m79374 21.1%   
Total revenues Rs m4,28992,230 4.7%   
Gross profit Rs m56920,367 2.8%  
Depreciation Rs m2042,644 7.7%   
Interest Rs m4302,373 18.1%   
Profit before tax Rs m1315,724 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m63,827 0.2%   
Profit after tax Rs m511,088 0.0%  
Gross profit margin %13.522.2 60.9%  
Effective tax rate %48.024.3 197.4%   
Net profit margin %0.112.1 0.9%  
BALANCE SHEET DATA
Current assets Rs m6,85268,746 10.0%   
Current liabilities Rs m6,71127,027 24.8%   
Net working cap to sales %3.345.4 7.4%  
Current ratio x1.02.5 40.1%  
Inventory Days Days16185 189.2%  
Debtors Days Days31896 333.4%  
Net fixed assets Rs m3,67324,132 15.2%   
Share capital Rs m317282 112.2%   
"Free" reserves Rs m3,76144,643 8.4%   
Net worth Rs m4,07844,925 9.1%   
Long term debt Rs m1,67145,363 3.7%   
Total assets Rs m12,633117,639 10.7%  
Interest coverage x1.07.6 13.5%   
Debt to equity ratio x0.41.0 40.6%  
Sales to assets ratio x0.30.8 42.7%   
Return on assets %3.411.4 30.1%  
Return on equity %0.124.7 0.5%  
Return on capital %7.719.1 40.1%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96456,152 1.7%   
Fx outflow Rs m6078,084 7.5%   
Net fx Rs m35748,068 0.7%   
CASH FLOW
From Operations Rs m1,3456,574 20.5%  
From Investments Rs m-2,256-7,124 31.7%  
From Financial Activity Rs m-1,2005,432 -22.1%  
Net Cashflow Rs m-2,1111,992 -105.9%  

Share Holding

Indian Promoters % 4.5 48.3 9.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 6.9 -  
FIIs % 1.4 34.4 3.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 10.5 896.2%  
Shareholders   20,807 56,727 36.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  ORCHID PHARMA LTD  PFIZER  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; Pharma Stocks Witness Buying(12:30 pm)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the energy sector and pharma sector witnessing maximum buying interest.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Hindustan Aeronautics IPO: Yet Another Play on India's Defence Sector (IPO)

Mar 14, 2018

Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?

Bharat Dynamics IPO: Worth Betting on Defence Manufacturing? (IPO)

Mar 12, 2018

Should you apply for the IPO of Bharat Dynamics, India's first state-owned missile manufacturer?

More Views on News

Most Popular

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS